SS Innovations Showcases Long-Distance Robotic Cardiac Surgery, Highlighting Potential to Extend Specialist Care

SS Innovations demonstrated remote robotic cardiac surgery at international conferences, underscoring the potential of telesurgery to deliver specialist expertise beyond major medical centers.

Chicago Metrowire Staff
••Healthcare
SS Innovations Showcases Long-Distance Robotic Cardiac Surgery, Highlighting Potential to Extend Specialist Care

SS Innovations International (NASDAQ: SSII) demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026, performing a robotic-assisted cardiac procedure from approximately 7,500 miles away. The demonstrations underscore the growing feasibility of remote robotic surgery, which could extend specialist expertise to patients far from major medical centers, though widespread adoption still depends on clinical validation, connectivity, and regulatory clearances.

At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, remotely performed an atrial septal defect procedure on a patient located in Bengaluru, India. The company also reported that four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric, and gynecological procedures. As of October 23, 2026, SS Innovations said 205 telesurgeries have been performed using the SSi Mantra system, including cardiac procedures.

The ability to perform complex cardiac surgery remotely has significant implications for healthcare access. If validated and adopted, such technology could allow highly specialized surgeons to treat patients in underserved or remote regions without the need for travel, potentially reducing delays in care and improving outcomes. However, the company acknowledged that broader adoption will require clinical validation, reliable connectivity, and appropriate regulatory frameworks.

SS Innovations is currently pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA’s review process. FDA clearance would mark a critical step toward commercial availability in the United States, the world’s largest medical device market, and could accelerate adoption of remote robotic surgery if the technology proves safe and effective in clinical trials.

The company’s showcase at major industry events also serves to position SS Innovations in the competitive surgical robotics field, where established players and new entrants are racing to develop and validate telesurgery capabilities. For investors, the demonstrations provide a tangible example of the SSi Mantra’s capabilities and the company’s progress toward regulatory milestones. More details about the demonstrations are available through the company’s SS Innovations (NASDAQ: SSII) profile, and the full announcement can be Read More. The latest updates relating to SSII are also available in the company’s newsroom at https://ibn.fm/SSII. This article was originally distributed by www.newmediawire.com.

Blockchain Registration

QR Code for Blockchain Registration